These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31832728)

  • 1. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of peptide receptor radionuclide therapy with
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
    Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
    [No Abstract]   [Full Text] [Related]  

  • 4. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of
    Liu Q; Zang J; Sui H; Ren J; Guo H; Wang H; Wang R; Jacobson O; Zhang J; Cheng Y; Zhu Z; Chen X
    J Nucl Med; 2021 Mar; 62(3):386-392. PubMed ID: 32826319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Single Low-dose
    Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
    Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
    Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
    Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 8. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of [
    Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
    J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
    Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
    Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of peptide receptor radionuclide therapy with
    Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y
    Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
    Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraindividual comparison of [
    Hänscheid H; Hartrampf PE; Schirbel A; Buck AK; Lapa C
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2566-2572. PubMed ID: 33452632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
    Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
    Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
    Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of pretherapy [
    Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
    Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lutetium [
    Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3417-3427. PubMed ID: 38772998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.